Skip to Content


Active Substance: pramipexole dihydrochloride monohydrate
Common Name: pramipexole
ATC Code: N04BC05
Marketing Authorisation Holder: Dr. Karl Thomae GmbH
Active Substance: pramipexole dihydrochloride monohydrate
Status: Withdrawn
Authorisation Date: 1997-10-27
Therapeutic Area: Parkinson Disease
Pharmacotherapeutic Group: Anti-parkinson drugs

Therapeutic Indication

DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).

The marketing authorisation for Daquiran has been withdrawn at the request of the marketing authorisation holder. 

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.